June 2021. Volume 17. Number 2

Bronchodilators in bronchiolitis: should we reassess their selective use?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Rodríguez‐Martínez CE, Nino G, Castro‐Rodríguez JA, Pérez GF, Sossa‐Briceño MP, Buendía JA. Cost‐effectiveness analysis of phenotypic‐guided versus guidelines‐guided bronchodilator therapy in viral bronchiolitis. Ped Pulmonol. 2021;56:187-95.

Reviewers: Ochoa Sangrador C1, Gimeno Díaz de Atauri Á2.
1Servicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
2Servicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 27/05/2021
Acceptance date: 02/06/2021
Publication date: 09/06/2021

Abstract

Authors’ conclusions: compared to guidelines‐guided strategy, treating infants with viral bronchiolitis using the phenotypic‐guided bronchodilator therapy strategy is a more cost‐effective strategy, because it involves a lower probability of hospital admission at lower total treatment costs. Randomized controlled trials using biomarkers to stratify patients most likely to respond to bronchodilators are necessary.

Reviewers’ commentary: the available information does not seem sufficient to make changes to the current recommendations in acute bronchiolitis management. There is still need for a predictive model that allows to identify potential responders to bronchodilators, as well as a clinical trial with a sufficient sample size to estimate the effectiveness of the strategy of its selective use.

How to cite this article

Ochoa Sangrador C, Gimeno Díaz de Atauri A. Broncodilatadores en bronquiolitis: ¿debemos replantearnos su uso selectivo? Evid Pediatr. 2021;17:18.

AVC | Critically appraised articles

Rodríguez‐Martínez CE, Nino G, Castro‐Rodríguez JA, Pérez GF, Sossa‐Briceño MP, Buendía JA. Cost‐effectiveness analysis of phenotypic‐guided versus guidelines‐guided bronchodilator therapy in viral bronchiolitis. Ped Pulmonol. 2021;56:187-95.

Reviewers: Ochoa Sangrador C1, Gimeno Díaz de Atauri Á2.
1Servicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
2Servicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 27/05/2021
Acceptance date: 02/06/2021
Publication date: 09/06/2021

How to cite this article

Ochoa Sangrador C, Gimeno Díaz de Atauri A. Broncodilatadores en bronquiolitis: ¿debemos replantearnos su uso selectivo? Evid Pediatr. 2021;17:18.

09/06/2021

Linked Comment